Man Group’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $799K | Buy |
+52,718
| New | +$798K | ﹤0.01% | 1925 |
|
|
2025
Q2 | – | Sell |
-15,181
| Closed | -$271K | – | 2319 |
|
|
2025
Q1 | $271K | Buy |
+15,181
| New | +$345K | ﹤0.01% | 1963 |
|
|
2024
Q3 | – | Sell |
-300,171
| Closed | -$5.14M | – | 2129 |
|
|
2024
Q2 | $5.14M | Sell |
300,171
-243,653
| -45% | -$4.29M | 0.01% | 998 |
|
|
2024
Q1 | $8.5M | Buy |
543,824
+386,436
| +246% | +$5.68M | 0.02% | 771 |
|
|
2023
Q4 | $2.35M | Buy |
+157,388
| New | +$2.11M | 0.01% | 1228 |
|
|
2023
Q3 | – | Sell |
-99,857
| Closed | -$2.88M | – | 1126 |
|
|
2023
Q2 | $4.14M | Buy |
+99,857
| New | +$6.2M | 0.01% | 957 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 883 |
|
|
2022
Q4 | – | Sell |
-2,990
| Closed | -$227K | – | 2141 |
|
|
2022
Q3 | $227K | Buy |
+2,990
| New | +$233K | ﹤0.01% | 1740 |
|
|
2022
Q2 | – | Sell |
-35,722
| Closed | -$2.96M | – | 2304 |
|
|
2022
Q1 | $2.96M | Sell |
35,722
-49,448
| -58% | -$3.64M | 0.01% | 1093 |
|
|
2021
Q4 | $6.39M | Sell |
85,170
-2,916
| -3% | -$293K | 0.02% | 783 |
|
|
2021
Q3 | $10.2M | Buy |
88,086
+45,727
| +108% | +$6.91M | 0.04% | 565 |
|
|
2021
Q2 | $9.4M | Buy |
42,359
+1,077
| +3% | +$210K | 0.03% | 603 |
|
|
2021
Q1 | $5.46M | Buy |
41,282
+4,275
| +12% | +$676K | 0.02% | 643 |
|
|
2020
Q4 | $6.4M | Sell |
37,007
-32,282
| -47% | -$4.42M | 0.03% | 659 |
|
|
2020
Q3 | $7.71M | Buy |
69,289
+10,415
| +18% | +$833K | 0.03% | 597 |
|
|
2020
Q2 | $3.49M | Buy |
58,874
+33,437
| +131% | +$2.2M | 0.02% | 833 |
|
|
2020
Q1 | $1.71M | Sell |
25,437
-10,949
| -30% | -$865K | 0.01% | 943 |
|
|
2019
Q4 | $3.07M | Buy |
36,386
+26,086
| +253% | +$2.11M | 0.01% | 1177 |
|
|
2019
Q3 | $770K | Sell |
10,300
-34,226
| -77% | -$2.74M | ﹤0.01% | 1496 |
|
|
2019
Q2 | $2.82M | Buy |
44,526
+36,533
| +457% | +$1.85M | 0.01% | 1192 |
|
|
2019
Q1 | $385K | Sell |
7,993
-5,991
| -43% | -$288K | ﹤0.01% | 1766 |
|
|
2018
Q4 | $468K | Sell |
13,984
-156,772
| -92% | -$5.73M | ﹤0.01% | 1642 |
|
|
2018
Q3 | $8.95M | Buy |
170,756
+22,631
| +15% | +$901K | 0.03% | 685 |
|
|
2018
Q2 | $4.64M | Buy |
148,125
+6,208
| +4% | +$173K | 0.02% | 989 |
|
|
2018
Q1 | $3.09M | Buy |
+141,917
| New | +$3.05M | 0.01% | 1096 |
|
Other funds holding NVCR
SCM
QCM
Man Group's NVCR Position: Q2 2026 in Review
Man Group opened a new position in NovoCure (NVCR) in Q2 2026: 52,718 shares worth $799K. The stake represents ﹤0.01% of the portfolio and ranks #1925 among its holdings. This is a return to the name: Man Group previously reported a position in NVCR as recently as Q1 2025.
Man Group first reported a position in NVCR in Q1 2018 and has held it in 24 quarters since. The position peaked at $10.2M in Q3 2021. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.
- Man Group held 52,718 shares of NovoCure worth $799K as of Q2 2026.
- NovoCure was a new Man Group position in Q2 2026.
- NovoCure made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1925 holding.
- Man Group first reported a position in NovoCure in Q1 2018 and has held it in 24 quarters since.
- Man Group's NovoCure position peaked at $10.2M in Q3 2021.
- 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.
Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.